In this episode:

• We are back talking with Mike Hu about Project GUARDIAN.
• Project GUARDIAN advocates for and supports sequencing based newborn screening to identify pre-symptomatic patients who can either benefit from early intervention using existing treatments or eligible for clinical trials of novel treatments, at a disease stage when treatment could be maximally efficacious.
• We discuss what genome sequencing is and the role it can play in diagnosis of rare diseases in the future.
• We also discussed epigenetic modifications that are specific to an individual.
• How is genomic sequencing different than mass spectrometry and how could it transform newborn screening? Mike unpacks his vision.
• When we talk about expansion of the newborn screening system, it is necessary to introduce new platforms that go beyond mass spectrometry, and genomic sequencing is a suitable one.
• We discuss the challenges introducing large scale sequence based newborn screening studies in the US. 

The  National MPS Society exists to cure, support, and advocate for MPS and ML.

If you like Our Voices, visit our website and follow us on social media on Facebook, Instagram, Twitter, and LinkedIn. And if you like the podcast, we'd appreciate you telling a friend (maybe even two).